4-甲基-2-苯基-1,3-恶唑-5-甲酰胺 | 51655-70-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-甲基-2-苯基-1,3-恶唑-5-甲酰胺
• 英文名称: 5-Carbamyl-4-methyl-2-phenyloxazol
• 英文别名: 4-methyl-2-phenyl-oxazole-5-carboxylic acid amide；5-carbamoyl-4-methyl-2-phenyloxazole；5-Oxazolecarboxamide, 4-methyl-2-phenyl-；4-methyl-2-phenyl-1,3-oxazole-5-carboxamide
• CAS: 51655-70-0
• 化学式: C₁₁H₁₀N₂O₂
• 分子量: 202.213
• InChiKey: HWVUBEDCKFTLCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  69.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-甲基-2-苯基-1,3-噁唑-5-羧酸乙酯 在 氨 作用下， 生成 4-甲基-2-苯基-1,3-恶唑-5-甲酰胺
  参考文献：
  名称：

  Tarzia,G. et al., European Journal of Medicinal Chemistry, 1976, vol. 11, p. 263 - 270

  摘要：

  DOI：

文献信息

• Pyrazole compounds and their use as antidiabetes agents
  申请人：Takagi Masaki

  公开号：US20070032529A1

  公开（公告）日：2007-02-08

  The present invention provides a pyrazole compound that has liver glycogen phosphorylase inhibitory activity and is useful as a therapeutic or prophylactic agent for diabetes, the pyrazole compound represented by the following general formula (I): wherein Ring Q represents an aryl or heteroaromatic group, R 1 represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group or a C 1-6 alkoxy group, R 2 represents a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group or an azido group, R 3 represents a halogen atom, a hydroxyl group, a C 1-6 alkyl group, a halo C 1-6 alkyl group, a C 1-6 alkoxy group, an azido group, an amino group, an acylamino group or a C 1-6 alkylsulfonylamino group, R 4 and R 5 are identical with or different from each other and represent a hydrogen atom, a substituted or unsubstituted C 1-6 alkyl group, a C 3-8 cycloalkyl group, a substituted or unsubstituted saturated heterocyclic group, a substituted or unsubstituted aryl group, a C 7-14 aralkyl group, a heteroaromatic group, or the like, or a pharmacologically acceptable salt thereof.

  本发明提供了一种具有肝糖原磷酸化酶抑制活性的吡唑化合物，用作糖尿病的治疗或预防剂，所述吡唑化合物由以下通用式（I）表示：其中环Q代表芳基或杂芳基，R1代表氢原子、卤原子、C1-6烷基或C1-6烷氧基，R2代表卤原子、C1-6烷基、C1-6烷氧基或偶氮基，R3代表卤原子、羟基、C1-6烷基、卤代C1-6烷基、C1-6烷氧基、偶氮基、氨基、酰胺基或C1-6烷基磺酰胺基，R4和R5彼此相同或不同，代表氢原子、取代或未取代的C1-6烷基、取代或未取代的C3-8环烷基、取代或未取代的饱和杂环基、取代或未取代的芳基、C7-14芳基烷基、杂芳基等，或其药理学上可接受的盐。
• Monoamino 2,4,5-trisubstituted oxazoles
  申请人：Gruppo Lepetit S.p.A.

  公开号：US04072689A1

  公开（公告）日：1978-02-07

  Pharmacologically active 2,4,5-trisubstituted oxazoles of the general formula ##STR1## wherein A is cyclohexyl, thienyl or a group of the formula ##STR2## in which R represents one to three substituents each independently selected from the group consisting of hydrogen, lower alkyl, halo, halo-lower alkyl, lower alkoxy, nitro, cyano, amino, carbamoyl, acetamino or carboxy; one of the R.sub.1 and R.sub.2 groups is a lower alkyl group and the other is an amido group, ##STR3## wherein R.sub.3 is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, cycloalkyl, phenyl, substituted phenyl, phenyl-lower alkyl, hydroxy-lower alkyl, lower acyloxy-lower alkyl, hydroxy, amino, lower alkylideneamino, cycloalkylideneamino, benzylideneamino and R.sub.4 is selected from hydrogen, lower alkyl, lower alkenyl, cycloalkyl, phenyl, substituted phenyl, phenyl-lower alkyl, hydroxy-lower alkyl, lower acyloxy-lower alkyl, or R.sub.3 and R.sub.4 taken together with the nitrogen atom may also form a 5- to 7-membered hetero ring which may contain one other hetero atom selected from N, O and S. The compounds have antiinflammatory activity.

  药理活性的2,4,5-三取代噁唑的通式为##STR1##其中A为环己基，噻吩基或公式##STR2##的基团，其中R代表从氢，低级烷基，卤素，卤素-低级烷基，低级烷氧基，硝基，氰基，氨基，氨基甲酰基，乙酰氨基或羧基选择的一个至三个取代基，R.sub.1和R.sub.2基团中的一个是低级烷基基团，另一个是酰胺基团，##STR3##其中R.sub.3选择自氢，低级烷基，低级烯基，环烷基，苯基，取代苯基，苯基-低级烷基，羟基-低级烷基，低级酰氧基-低级烷基，羟基，氨基，低级烷基亚胺基，环烷基亚胺基，苄亚胺基和R.sub.4选择自氢，低级烷基，低级烯基，环烷基，苯基，取代苯基，苯基-低级烷基，羟基-低级烷基，低级酰氧基-低级烷基，或R.sub.3和R.sub.4与氮原子一起也可以形成一个5-至7-成员的杂环，其中可能包含另一个从N，O和S选择的杂原子。这些化合物具有抗炎活性。
• PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME
  申请人：Japan Tobacco, Inc.

  公开号：EP1884513A1

  公开（公告）日：2008-02-06

  The present invention provides a pyrazole compound that has liver glycogen phosphorylase inhibitory activity and is useful as a therapeutic or prophylactic agent for diabetes, the pyrazole compound represented by the following general formula (I): wherein Ring Q represents an aryl or heteroaromatic group, R1 represents a hydrogen atom, a halogen atom, a C1-6 alkyl group or a C1-6 alkoxy group, R2 represents a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group or an azido group, R3 represents a halogen atom, a hydroxyl group, a C1-6 alkyl group, a halo C1-6 alkyl group, a C1-6 alkoxy group, an azido group, an amino group, an acylamino group or a C1-6 alkylsulfonylamino group, R4 and R5 are identical with or different from each other and represent a hydrogen atom, a substituted or unsubstituted C1-6 alkyl group, a C3-8 cycloalkyl group, a substituted or unsubstituted saturated heterocyclic group, a substituted or unsubstituted aryl group, a C7-14 aralkyl group, a heteroaromatic group, or the like, or a pharmacologically acceptable salt thereof.

  本发明提供了一种具有肝糖原磷酸化酶抑制活性并可用作糖尿病治疗或预防剂的吡唑化合物，该吡唑化合物由以下通式(I)表示： 其中环 Q 代表芳基或杂芳基，R1 代表氢原子、卤素原子、C1-6 烷基或 C1-6 烷氧基，R2 代表卤素原子、C1-6 烷基、C1-6 烷氧基或叠氮基，R3 代表卤素原子、羟基、C1-6 烷基、卤代 C1-6 烷基、C1-6 烷氧基、叠氮基、氨基、酰氨基或酰胺基、R4 和 R5 彼此相同或不同，代表氢原子、取代或未取代的 C1-6 烷基、C3-8 环烷基、取代或未取代的饱和杂环基、取代或未取代的芳基、C7-14 芳基、杂芳基或类似基团，或其药理学上可接受的盐。
• TARZIA G.; SCHIATTI P.; SELVA D.; FAVARA D.; CERIANI S., EUR. J. MED. CHEM., 1976, 11, NO 3, 263-270
  作者：TARZIA G.、 SCHIATTI P.、 SELVA D.、 FAVARA D.、 CERIANI S.

  DOI：——

  日期：——
• US4072689A
  申请人：——

  公开号：US4072689A

  公开（公告）日：1978-02-07